EUCTR2020-005933-34-NL
Active, not recruiting
Phase 1
Evaluation of a modified Anti-Platelet Therapy associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy - TARGET FIRST
Sorin CRM SAS (Microport CRM)0 sites2,246 target enrollmentApril 22, 2021
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Sorin CRM SAS (Microport CRM)
- Enrollment
- 2246
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects must meet all of the following criteria to be eligible for enrolment:
- •Subject is \= 18 years old
- •Subject has been hospitalised for troponin\-positive Non\-ST\-Elevation MI, requiring early invasive treatment (PCI), or ST\-Elevation MI requiring primary PCI, and this PCI occurred within the last 7 days
- •Subject is eligible for per\-protocol antiplatelet treatments
- •Subject understands and agrees with the trial requirements and procedures, and provides written informed consent before any trial\-specific tests or procedures are performed
- •Subject is willing to comply with all protocol requirements including antiplatelet treatment strategies and follow\-up visits
- •Procedural/angiographic (related to the treatment of the (N)STEMI
- •Successful revascularization:
- •\-Successful delivery and deployment of the Firehawk stent(s), with final residual stenosis of \<30% (visually) for all target lesions
- •\-No occurrence of significant event (such as MI, unplanned revascularisation, stent thrombosis, stroke, major vascular complication/bleeding).
Exclusion Criteria
- •Patients fulfilling any of the following criteria are not eligible:
- •Subjects with prior STEMI or prior PCI within 12 months before index admission
- •Prior Coronary Artery Bypass Graft (CABG) Surgery
- •Cardiogenic shock
- •Secondary PCI
- •Fibrinolysis
- •Prior stent thrombosis
- •Planned PCI, CABG, or surgery within 12 months after the enrolment
- •Need for Oral Anti\-Coagulation medications (or NOAC)
- •Ischemic stroke or intracerebral hemorrhage (spontaneous or traumatic) within 12 months prior to index procedure
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A study designed to evaluate a modified Anti-Platelet Therapy (drugs that prevent blood platelets from clotting) after implantation of a Firehawk drug-eluting stent (metallic tube, which is covered with a drug and inserted into stenosed blood vessels of the heart in order to keep them open) in patients who have experienced a heart attack and were treated with complete revascularisation (the lesion related to the heart attack and all other significant lesions were treated)EUCTR2020-005933-34-ESSorin CRM SAS (Microport CRM)2,246
Active, not recruiting
Phase 1
A study designed to evaluate a modified Anti-Platelet Therapy (drugs that prevent blood platelets from clotting) after implantation of a Firehawk drug-eluting stent (metallic tube, which is covered with a drug and inserted into stenosed blood vessels of the heart in order to keep them open) in patients who have experienced a heart attack and were treated with complete revascularisation (the lesion related to the heart attack and all other significant lesions were treated)Patients with clinically stable, low to moderate complexity acute Myocardial Infarction (MItroponine-positive Non-ST-Elevation MI or ST-Elevation MI) requiring primary Percutaneous Coronary Intervention. Subjects will be enrolled after having undergone successful complete revascularization with the study stent (Firehawk). Shortened DAPT of 1 month followed by 11 months P2Y12-Inhibitor only is compared to the current guideline-recommended 12-months DAPT.MedDRA version: 20.0Level: SOCClassification code 10007541Term: Cardiac disordersSystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2020-005933-34-ATSorin CRM SAS (Microport CRM)2,246
Terminated
Not Applicable
Comparison of the effect of an anti-platelet intervention with Ticagrelor versus placebo on participants with asymptomatic elevations in troponin TACTRN12614000189628Professor Derek Chew420
Completed
Phase 4
The efficacy and safety of the antiplatelet therapy in acute non-cardiogenic ischemic stroke.on-cardiogenic ischemic stroke in acute phase.JPRN-UMIN000006931Department of Neurosurgery, Faculty of Medicine, University of Tsukuba130
Completed
Not Applicable
Controlled Anti-platelet medical therapy based on rapid CYP2C19 gene evaluation in Acute myocardial infarctioAcute myocardial infarctionJPRN-UMIN000008151Graduate School of Medical Sciences, Kumamoto University100